Please login to the form below

Not currently logged in


This page shows the latest EpiDestiny news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

And as an oral, once-daily drug EpiDestiny’s candidate could be easier to administer - and likely much cheaper - than gene therapies that are in development for SCD and beta-thalassaemia. ... EpiDestiny is hanging on to rights for the drug as a cancer

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Time to talk about health inequalities
Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...